Visualizar por autor "Vázquez Bourgon, Javier"

A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis

Vázquez Bourgon, Javier

; Mata Pastor, Ignacio; Roiz Santiáñez, Roberto Miguel; Ayesa Arriola, Rosa

; Suárez Pinilla, Paula

; Tordesillas Gutiérrez, Diana

; Vázquez Barquero, José Luis

; Crespo Facorro, Benedicto

(Korean Neuropsychiatric Association, 2014)

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone

Gómez Revuelta, Marcos; Pelayo Terán, José María; Juncal Ruiz, María; Vázquez Bourgon, Javier

; Suárez Pinilla, Paula

; Romero Jiménez, Rodrigo; Setién Suero, María Esther; Ayesa Arriola, Rosa

; Crespo Facorro, Benedicto

(Oxford University Press, 2020-01-24)

Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression

Gómez Revuelta, Marcos; Fernández Rodríguez, María; Boada Antón, Laura; Vázquez Bourgon, Javier

(SAGE journals, 2020-01-01)

Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol

Mas, Sergi; Juliá, Laura; Cuesta, Manuel J.; Crespo Facorro, Benedicto

; Vázquez Bourgon, Javier

; Spuch, Carlos; González-Pinto, Ana; Ibáñez, Ángela; Usall, Judith; Romero-López-Alberca, Cristina; Catalán, Ana; Mané. Anna; Bernardo, Miquel (Frontiers Media, 2024)

Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis

Vázquez Bourgon, Javier

; Ortiz-García de la Foz, Víctor; Gómez Revuelta, Marcos; Mayoral-van Son, Jacqueline; Juncal Ruiz, María; Garrido-Torres, Nathalia; Crespo Facorro, Benedicto

(2022)

Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis

Crespo Facorro, Benedicto

; Ruiz-Veguilla, Miguel; Vázquez Bourgon, Javier

; Sánchez-Hidalgo, Ana C.; Garrido-Torres, Nathalia; Cisneros, Jose M.; Prieto, Carlos; Sainz Maza, Jesús Vicente (Frontiers Media, 2021-03-02)

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial

Garrido-Sánchez, Lucía; Gómez-Revuelta, Marcos; Ortiz-García de la Foz, Víctor; Pelayo-Terán, José María; Juncal-Ruiz, María; Ruiz-Veguilla, Miguel; Mayoral-Van Son, Jacqueline; Ayesa Arriola, Rosa

; Vázquez Bourgon, Javier

; Crespo Facorro, Benedicto

(Oxford University Press, 2022)

Asocciations between environmental factors, extreme stressful life events (ELSE), and first-episode psychosis (FEP): a naturalistic approach

Serrano Pérez, María Luisa (2024-06-24)

Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment

Tomasik, Jakub; Lago, Santiago G.; Vázquez Bourgon, Javier

; Papiol, Sergi; Suárez Pinilla, Paula

; Crespo Facorro, Benedicto

; Bahn, Sabine (American Medical Association (AMA), 2019-04)

Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients

Vázquez Bourgon, Javier

; Ortiz-García de la Foz, Víctor; Suarez Pereira, Irene; Iruzubieta, Paula; Arias Loste, María Teresa

; Setién Suero, María Esther; Ayesa Arriola, Rosa

; Gómez Revuelta, Marcos; Crespo García, Javier

; Crespo Facorro, Benedicto

(Elsevier, 2019-12)

Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis

Pelayo Terán, José María; Pérez Iglesias, Rocio; Vázquez Bourgon, Javier

; Mata Pastor, Ignacio; Carrasco Marín, Eugenio; Vázquez Barquero, José Luis

; Crespo Facorro, Benedicto

(Elsevier, 2011-01-30)

Characterising negative symptoms in schizophrenia: CHANSS study protocol

Wolpe, Noham; Aymerich, Clàudia; Jin, Ying; Martin-Subero, Marta; Fuentes Pérez, Paloma Guadalupe; Ovejas Catalán, Claudia; Salas-Rad, Sara; Zirilli, Renata; Shaford, Sophie; Cox, Rebeca; Cartier, Megan; Catalán, Ana; Mane, Anna; Pratt, John; Airey, Lisa; Stanley, Paul; Close, Adrianne; Hall, Andrew; Vázquez Bourgon, Javier

; [et al.] (Cambridge University Press, 2025)

Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium

Smart, Sophie E.; Agbedjro, Deborah; Pardiñas, Antonio F.; Ajnakina, Olesya; Alameda, Luis; Andreassen, Ole A.; Barnes, Thomas R. E.; Berardi, Domenico; Camporesi, Sara; Cleusix, Martine; Conus, Philippe; Crespo Facorro, Benedicto

; D'Andrea, Giuseppe; Demjaha, Arsime; Di Forti, Marta; Do, Kim; Doody, Gillian; Eap, Chin B.; Ferchiou, Aziz; [et al.] (Elsevier, 2022)

Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study

Millgate, Edward; Smart, Sophie E.; Pardiñas, Antonio F.; Kravariti, Eugenia; Ajnakina, Olesya; Kepinska, Adrianna P.; Andreassen, Ole A.; Barnes, Thomas R.E.; Berardi, Domenico; Crespo Facorro, Benedicto

; D'Andrea, Giuseppe; Demjaha, Arsime; Di Forti, Marta; Doody, Gillian A.; Kassoumeri, Laura; Ferchiou, Aziz; Guidi, Lorenzo; Joyce, Eileen M.; Vázquez Bourgon, Javier

; [et al.] (Elsevier, 2023)

Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions

Van der Horst, Marte Z; Meijer, Y; De Boer, N; Guloksuz, S; Hasan, A; Siskind, D; Wagner, E; Okhuijsen-Pfeifer, C; Vázquez Bourgon, Javier

(Elsevier, 2023)

Contacto con los servicios de Atención Primaria previo al diagnóstico de un primer episodio psicótico en Cantabria

Sánchez Gallego, Nazareth María (2024-06)

COVID-19 and mental health in primary care professionals in Cantabria

Corona Gutiérrez, Carmen (2022-09-07)

Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program

Pardo de Santayana Jenaro, Guillermo; Vázquez Bourgon, Javier

; Gómez Revuelta, Marcos; Ayesa Arriola, Rosa

; Ortiz Garcia de la Foz, Victor; Crespo Facorro, Benedicto

; Pelayo Terán, José María (Elsevier BV, 2020-04-23)

Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis

Vázquez Bourgon, Javier

; Ortiz García de la Foz, Víctor; Suarez Pereira, Irene; Iruzubieta, Paula; Arias Loste, María Teresa

; Setién Suero, María Esther; Ayesa Arriola, Rosa

; Gómez Revuelta, Marcos; Crespo García, Javier

; Crespo Facorro, Benedicto

(Elsevier BV, 2019-12)

Depresión y ansiedad en la EPOC. Repercusión, identificación y manejo

Vázquez Bourgon, Javier

(Neumología y Salud, 2019-04)

Visualizar por autor "Vázquez Bourgon, Javier"

A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone

Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression

Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol

Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis

Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial

Asocciations between environmental factors, extreme stressful life events (ELSE), and first-episode psychosis (FEP): a naturalistic approach

Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment

Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients

Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis

Characterising negative symptoms in schizophrenia: CHANSS study protocol

Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium

Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study

Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions

Contacto con los servicios de Atención Primaria previo al diagnóstico de un primer episodio psicótico en Cantabria

COVID-19 and mental health in primary care professionals in Cantabria

Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program

Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis

Depresión y ansiedad en la EPOC. Repercusión, identificación y manejo

Listar

Mi cuenta

Sobre UCrea

Piensa en abierto

Compartir

Visualizar por autor "Vázquez Bourgon, Javier"

A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis ﻿

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone ﻿

Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression ﻿

Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol ﻿

Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis ﻿

Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis ﻿

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial ﻿

Asocciations between environmental factors, extreme stressful life events (ELSE), and first-episode psychosis (FEP): a naturalistic approach ﻿

Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment ﻿

Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients ﻿

Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis ﻿

Characterising negative symptoms in schizophrenia: CHANSS study protocol ﻿

Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium ﻿

Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study ﻿

Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions ﻿

Contacto con los servicios de Atención Primaria previo al diagnóstico de un primer episodio psicótico en Cantabria ﻿

COVID-19 and mental health in primary care professionals in Cantabria ﻿

Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program ﻿

Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis ﻿

Depresión y ansiedad en la EPOC. Repercusión, identificación y manejo ﻿

A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone

Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression

Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol

Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis

Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial

Asocciations between environmental factors, extreme stressful life events (ELSE), and first-episode psychosis (FEP): a naturalistic approach

Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment

Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients

Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis

Characterising negative symptoms in schizophrenia: CHANSS study protocol

Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium

Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study

Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions

Contacto con los servicios de Atención Primaria previo al diagnóstico de un primer episodio psicótico en Cantabria

COVID-19 and mental health in primary care professionals in Cantabria

Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program

Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis

Depresión y ansiedad en la EPOC. Repercusión, identificación y manejo